Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab tirumotecan + Pembrolizumab in Adjuvant TNBC
NCT06393374Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2024
- Primary completion
- Dec 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 31
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in triple-negative breast cancer (TNBC), sponsored by Merck & Co.. Started Jun 2024; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06393374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06393374.